Are clinical trial data shared sufficiently today?

July 9, 2013, British Medical Journal

Ben Goldacre, research fellow at the London School of Hygiene and Tropical Medicine, says we need all the evidence to make informed decisions about medicines.

The lack of progress on has been startling, he writes. Current suggest that around half of all trials for the treatments being used today have gone unpublished; and that trials with positive results are twice as likely to be published.

There is mandating greater transparency – such as the law requiring trial results to be posted on the website – but the published evidence now shows that this legislation has been largely ignored.

He also calls for trials from the past to be fully disclosed, since more than 80% of the medicines prescribed this year came onto the market more than a decade ago.

Claims that it's enough for regulators to see all the information on trials expose patients to "real and unnecessary risks," he adds, because problems with evidence are also identified by and working outside of regulatory bodies.

He says that Clinical Study Reports – long documents held by regulators and companies on the full methods and results of trials – should be shared publicly, with information about individual patients redacted where necessary. He explains that 1.6 million pages of this material have already been shared by the European Medicines Agency (EMA).

GlaxoSmithKline – the world's fourth largest drug company – has also committed to share all Clinical Study Reports going back to the foundation of the company, as part of the AllTrials campaign.

On the issue of patient privacy, he does not call for individual from trials to be published openly, but does point to several examples of "sensible and cautious sharing of [these] detailed " among professionals.

The problem of missing trials "is one of the greatest ethical and practical problems facing medicine today," writes Goldacre. "The AllTrials movement is driving the solution forwards: patients need industry to engage constructively with this widespread consensus, on the practical details – urgently – so that we can all move on."

But John Castellani, President of the Pharmaceutical Research and Manufacturers of America (PhRMA), says mandatory disclosure could affect patient privacy, stifle discovery, and allow competitors or unscrupulous actors to use the information.

"The biopharmaceutical industry is firmly committed to enhancing public health through responsible reporting and publication of clinical research and safety information," he writes.

He points out that information on clinical trials for potential new medicines is already required by US law to be posted on - and says the industry is also "engaged in a dynamic ongoing process to improve on all aspects of clinical trials."

However, he warns that threats to "will jeopardize patient willingness to participate in clinical trials, which would delay the availability of new therapies."

Mandatory public disclosure of clinical trial information, without appropriate scientific and clinical context, could also undermine patient trust and confidence in the safety and effectiveness of approved medicines, he writes.

He also raises concerns over disclosure of intellectual property, confidential commercial information, and proprietary scientific methods found in clinical , saying this "could stifle discovery and open the possibility of competitors or unscrupulous actors using the information for their own products in other markets or countries."

He outlines the huge investment and "considerable risk" involved in the search for new treatments, and concludes that "only a carefully balanced regulatory and competitive environment can foster the future investments in this research necessary to produce new treatments to benefit current and future patients."

Explore further: Empowering children in clinical trials

More information:

Related Stories

Empowering children in clinical trials

June 20, 2013
There is evidence that over 50 percent of medicinal products developed for children have not been tested or authorised for use by this age group. The research project RESPECT ('Relating Expectations and Needs to Participation ...

Experts propose restoring invisible and abandoned trials 'to correct the scientific record'

June 13, 2013
Experts are today calling for all unpublished and misreported trials to be published or formally corrected within the next year to ensure doctors and patients rely on complete and accurate information to make decisions about ...

Patient expresses concern about lack of data on biological drugs

April 18, 2013
(HealthDay)—A patient with Crohn's disease is concerned about the attempt by the makers of adalimumab to prevent disclosure of trial data submitted during the drug's approval process, according to a personal view piece ...

Discrepant analyses of industry-sponsored clinical trials

January 29, 2013
Discrepancies between internal and published analyses of industry-sponsored clinical trials lead to further calls for transparency

New guidance urges improved reporting of important outcomes for patients in trials publications

February 28, 2013
Clinical trials provide us with the best evidence to guide patient treatment and inform health policy. Yet, crucial information, on outcomes reported directly by patients such as their quality of life, is often left out of ...

Public disclosure of clinical trial results by Health Canada should be mandatory

August 29, 2011
Health Canada is not prevented by law from publicly disclosing safety and efficacy data from clinical trials, pharmaceuticals, biologics and medical devices and should be more transparent, states an analysis in CMAJ (Canadian ...

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.